"The data for Celebrex is robust and exceeds, in the length of patients in studies and in the size of studies, the data Vioxx has," she said.
Momentum was growing for a fresh look at the safety of Celebrex and other pain relievers as key researchers, a congressman and European regulators said they feared such drugs might raise the risk of heart problems like those blamed on the arthritis medicine Vioxx.
On Sept. 30, the company took the dramatic step of withdrawing the drug, sending the price of its stock into a steep slide that wiped out a quarter of the company's value, a slide from which it has not yet recovered.
